Please provide your email address to receive an email when new articles are posted on . New position statement features two definitions of psoriasis severity: mild and moderate to severe. The change ...
Significant variability in symptoms and disease burden exists among myasthenia gravis patients across MGFA classes, challenging the use of MGFA classification for individual prognosis. Many patients ...
In September 2022, the US Food and Drug Administration (FDA) approved Sotyktu (deucravacitinib; Bristol-Myers Squibb Company), a tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results